TransCode Therapeutics (RNAZ) investor relations material

Executive summary

• Special Meeting called to approve key proposals related to stock issuances, acquisitions, and financing arrangements, all recommended by the Board of Directors.

• Proposals include conversion of Series A, B, and C Preferred Stock, issuance of shares under a Standby Equity Purchase Agreement (SEPA), and potential adjournment to solicit more votes if needed.

• Transactions involve significant acquisitions, licensing agreements, and financing to support oncology drug development and expand the therapeutic pipeline.

• Board obtained a fairness opinion from H.C. Wainwright & Co. confirming the financial fairness of the acquisition consideration.

Voting matters and shareholder proposals

• Proposal 1: Approve issuance of Common Stock upon conversion of Series A and B Preferred Stock, related to the acquisition of ABCJ/Polynoma and investment by DEFJ.

• Proposal 2: Approve issuance of Common Stock upon conversion of Series C Preferred Stock, related to the Unleash Immuno Oncolytics licensing agreement.

• Proposal 3: Approve issuance of Common Stock under SEPA and Convertible Notes with Yorkville, enabling up to $14 million in equity financing.

• Proposal 4: Approve adjournment of the meeting if more time is needed to secure votes for the above proposals.

• Board unanimously recommends voting FOR all proposals.

Board of directors and corporate governance

• Board composition and director removal require supermajority votes; vacancies filled by Board majority.

• Advance notice and meeting procedures limit shareholder-initiated actions and proposals.

• Anti-takeover provisions include staggered board, no written consent, and preferred stock issuance rights.